Cholesterol reduction by immunization with a PCSK9 mimic-Reference-Cited by-同舟云学术

Cholesterol reduction by immunization with a PCSK9 mimic

Published:2024-06 Issue:6 Volume:43 Page:114285
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Zhang Baoshan,Chuang Gwo-Yu,Biju Andrea,Biner Daniel,Cheng Jiaxuan,Wang Yiran,Bao Saran,Chao Cara W.,Lei Haotian,Liu Tracy,Nazzari Alexandra F.,Yang Yongping,Zhou Tongqing,Chen Steven J.,Chen Xuejun,Kong Wing-Pui,Ou Li,Parchment Danealle K.,Sarfo Edward K.,SiMa HaoMin,Todd John-Paul,Wang Shuishu,Woodward Ruth A.,Cheng Cheng,Rawi Reda,Mascola John R.,Kwong Peter D.^ORCID

Funder

National Cancer Institute

Empire State Development's Division of Science, Technology and Innovation

Simons Foundation

National Institute of Diabetes and Digestive and Kidney Diseases

National Institutes of Health

National Institute of Allergy and Infectious Diseases

National Institute of General Medical Sciences

Vaccine Research Center

Publisher

Elsevier BV

Reference57 articles.

1. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome;Schwartz;N. Engl. J. Med.,2018

2. Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial;Koren;Circulation,2014

3. Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Reduces Cholesterol Concentrations of All Serum Low-Density Lipoprotein Cholesterol Fractions;Toth;Circulation,2013

4. An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors;Choi;Cardiovasc. Ther.,2023

5. PCSK9 inhibitors - mechanisms of action;Page;Aust. Prescr.,2016